Source: PR Newswire
Lamassu Biotech has partnered with The Ohio State University College of Veterinary Medicine to advance RABI-767, a promising new treatment for acute pancreatitis, a life-threatening condition with no current effective therapies in humans or animals. The collaboration will focus on canine clinical trials, using naturally occurring cases in dogs to evaluate dosing strategies and effectiveness. This translational medicine approach could accelerate treatment development for both dogs and humans.
The partnership also marks the launch of Lamassu Pets, a new division dedicated to developing Veterinary applications of RABI-767. Preclinical studies and Phase 1 human trials have already shown the drug’s potential to reduce mortality and complications. Trials in dogs will inform human Phase 2 clinical development, conducted in partnership with Arrivo Bioventure. Developed with the Mayo Clinic, RABI-767 is administered by injection near the pancreas to reduce symptoms and protect against organ failure. Both partners aim to bring this novel treatment to patients and pets swiftly.